Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Baltimore, Maryland 21287


Purpose:

Ciprofloxacin hydrochloride has been approved by the Food and Drug Administration (FDA) for the treatment of mild to moderate infections, including prostate infections. It has been suggested that antibiotic treatment influences PSA levels due to the fact that an increase in PSA levels may be caused by inflammation or swelling of the prostate. Antibiotics are used to treat such inflammatory conditions. However, it has not been proven that antibiotics can be used to lower PSA. This research is being done to see if treatment with the antibiotic Ciprofloxacin hydrochloride affects the Prostate-Specific Antigen (PSA) blood test. This study may also help doctors in deciding which patients need a prostate biopsy.


Study summary:

This study is directed towards men who have been referred to the Urology clinic at the Johns Hopkins Outpatient Center in Baltimore, MD. If a patient fits the eligibility criteria and signs a consent form, the patient will have his blood drawn for the first PSA measurement. The patient must return to the Johns Hopkins Outpatient Center one week later for a second PSA measurement. The patient will be randomized to receive treatment with placebo or Ciprofloxacin hydrochloride for 14 days. The patient must return to the Johns Hopkins Outpatient Center at the end of the treatment cycle for the third PSA measurement. The patient will return one week later for his biopsy and fourth PSA measurement.


Criteria:

Inclusion Criteria: - Must be a patient of Johns Hopkins Urology Outpatient Clinic - Must have an elevated PSA (> 2.5 ng/mL) and be selected on the basis of a serum PSA evaluation for TRUS/biopsy - Must be able to understand and willing to adhere to the study protocol - Must be willing to take the antibiotic or placebo for two weeks prior to the biopsy and agree to have the biopsy regardless of the change in PSA Exclusion Criteria: - Abnormal digital rectal examination - Anyone currently being treated or who have been treated for any prostatic diseases (prostatitis, prostate BPH surgery, prostate cancer) or urinary tract infection in the past - Anyone taking medications that are likely to alter serum PSA concentration (specifically, androgen steroid hormones, antiandrogens, finasteride, LHRH analogues) - Anyone unwilling to sign the informed consent or who are unlikely to adhere to the study protocol - Anyone with a known allergy to fluoroquinolone antibiotics - Anyone on blood thinning medication (Coumadin) - Anyone taking Tizanidine - Anyone with a history of seizures or cerebral arteriosclerosis - Anyone who has taken an antibiotic medication within the past two weeks


NCT ID:

NCT00596453


Primary Contact:

Principal Investigator
Misop Han, M.D., M.S.
Johns Hopkins University


Backup Contact:

N/A


Location Contact:

Baltimore, Maryland 21287
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: January 19, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.